Thus, Eag1 inhibition, using a yet-to-be-developed highly selective and potent inhibitor, may have double benefits in the treatment of osteosarcoma; on one hand the inhibition of the osteosarcoma cell proliferation and on the other hand the stimulation of Ca2+ deposition into a terminal state of the bone matrix, which may be a new potential therapeutic strategy in cancer therapy. Here, KCNH1 is linked to osteosarcoma.